A PYMNTS Company

US: “Pharma Bro” Martin Shkreli to face antitrust suit

By  |  April 11, 2019

Martin Shkreli failed to convince a federal judge to dismiss an antitrust lawsuit against him on April 10, about a week after reports that the imprisoned “pharma bro” had been placed in solitary confinement, reported Bloomberg.

Shkreli, Retrophin, and two related companies are facing claims that they unlawfully shielded the blockbuster kidney drug Thiola from competition by refusing to put out samples that competing pharmaceutical companies must use, under federal law, to demonstrate the “bioequivalence” of their generics.

They will now have to undergo 90 days of limited discovery to determine whether plaintiff Spring Pharmaceuticals has standing to sue by virtue of the investment it made preparing to develop a generic Thiola rival, according to the ruling by Judge J. Curtis Joyner of the US District Court of the Eastern District of Pennsylvania.

Full Content: Big Law Business

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.